Long-term results show microstent device yields stable IOP with fewer medications
Four-year postoperative results show eyes with primary open-angle glaucoma (POAG) that received Hydrus Microstent (Ivantis Inc.) combined with cataract surgery (HS) maintained a stable IOP with significantly fewer glaucoma medications compared to cataract surgery (CS), according to a poster presented at AAO 2020 Virtual. In addition, HS group eyes were significantly less likely to require glaucoma surgery and there was no increase in endothelial cell density loss in the HS group compared to CS from 36 to 48 months.
For the study, 556 eyes with mild to moderate POAG on 1 to 4 glaucoma medications and washed out diurnal IOP of 22-34 mm Hg were randomized 2:1 HS or CS. Study groups were matched for baseline demographics and glaucoma characteristics. At 4 years, HS eyes were medication-free more frequently than CS eyes (65% vs 41%) while maintaining a similar mean IOP (16.7 mm HG vs 17.0 mm HG). In addition, eyes treated with HS had a lower 4-year risk of secondary glaucoma surgery (2.1% vs 6.0%. The treatment was safe with no between-group differences in visual acuity or safety findings were observed.
Radcliffe NM, et al. HORIZON Trial: Combined Hydrus Microstent and cataract surgery multicenter RCT: Four-year follow-up. Presented at: AAO 2020 Virtual [Session: PO192].